BCAX insider transaction filings
Bicara Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-14. Screen BCAX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Larson Jennifer — Chief Financial Officer | Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 18,750 @ $3.79 · Sale (S): 18,750 @ $27.98 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 10,000 @ $3.79 · Sale (S): 10,000 @ $27.98 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 12,500 @ $3.79 · Sale (S): 12,500 @ $27.97 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Oliger Christy J. — Director | Grant/award (A): 38,950 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Bender Jeremy — Director | Grant/award (A): 38,950 (derivative) @ $0 | EDGAR |
| 2026-07-14 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 10,000 @ $3.79 · Sale (S): 9,972 @ $28.42 · Sale (S): 28 @ $29.68 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 18,750 @ $3.79 · Sale (S): 22,833 @ $28.76 · Sale (S): 4,306 @ $29.80 · Sale (S): 1,075 @ $30.35 · Sale (S): 536 @ $29 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 12,500 @ $3.79 · Sale (S): 22,757 @ $28.60 · Sale (S): 4,413 @ $29.82 · Sale (S): 830 @ $30.31 · Option exercise (M): 11,592 (derivative) @ $0 · Option exercise (M): 908 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Mazumdar-Shaw Kiran — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Robertson Scott M. — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Simson Jake — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Haviland Kate — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Bowden Christopher — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | POWELL MICHAEL — Director | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 9,200 @ $3.79 · Sale (S): 9,200 @ $20.42 · Option exercise (M): 9,200 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 15,000 @ $3.79 · Sale (S): 12,022 @ $19.96 · Sale (S): 2,978 @ $20.35 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 8,000 @ $3.79 · Sale (S): 8,000 @ $20.29 · Sale (S): 4,500 @ $20.29 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Schelman William — Chief Medical Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Raben David — Chief Medical Officer | Option exercise (M): 5,500 @ $3.79 · Sale (S): 5,500 @ $22.88 · Option exercise (M): 5,500 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 9,200 @ $3.79 · Sale (S): 9,200 @ $23.00 · Option exercise (M): 9,200 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 8,226 @ $4.44 · Option exercise (M): 7,454 @ $3.79 · Option exercise (M): 7,080 @ $5.45 · Option exercise (M): 15,000 @ $3.79 · Sale (S): 15,000 @ $23.61 · Option exercise (M): 8,226 (derivative) @ $0 · +3 more | EDGAR |
| 2026-04-17 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 8,000 @ $3.79 · Sale (S): 8,000 @ $23.01 · Sale (S): 4,500 @ $23.01 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Raben David — Chief Medical Officer | Option exercise (M): 5,500 @ $3.79 · Sale (S): 5,500 @ $18.95 · Option exercise (M): 5,500 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 9,200 @ $3.79 · Sale (S): 9,200 @ $18.52 · Option exercise (M): 9,200 (derivative) @ $0 | EDGAR |
| 2026-03-20 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 6,499 @ $3.79 · Sale (S): 6,499 @ $18.84 · Option exercise (M): 6,905 @ $3.79 · Sale (S): 6,905 @ $18.78 · Option exercise (M): 1,596 @ $3.79 · Sale (S): 1,596 @ $18.95 · +3 more | EDGAR |
| 2026-03-17 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 8,000 @ $3.79 · Sale (S): 8,000 @ $19.66 · Sale (S): 4,500 @ $19.66 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 36,766 @ $3.79 · Sale (S): 36,766 @ $19.17 · Option exercise (M): 36,766 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 2,631 @ $3.79 · Sale (S): 2,631 @ $18.73 · Option exercise (M): 1,786 @ $3.79 · Sale (S): 1,786 @ $18.74 · Option exercise (M): 3,817 @ $3.79 · Sale (S): 3,817 @ $18.75 · +3 more | EDGAR |
| 2026-03-05 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 12,892 @ $3.79 · Sale (S): 12,892 @ $18.16 · Sale (S): 4,500 @ $18.16 · Option exercise (M): 12,892 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 7,318 @ $3.79 · Option exercise (M): 6,237 @ $3.79 · Sale (S): 13,555 @ $18.22 · Option exercise (M): 2,963 @ $3.79 · Sale (S): 2,963 @ $18.25 · Option exercise (M): 7,318 (derivative) @ $0 · +2 more | EDGAR |
| 2026-03-05 | 4 | Raben David — Chief Medical Officer | Option exercise (M): 200 @ $3.79 · Sale (S): 200 @ $18.45 · Option exercise (M): 16,300 @ $3.79 · Sale (S): 16,300 @ $18.52 · Option exercise (M): 200 (derivative) @ $0 · Option exercise (M): 16,300 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 300,000 @ $16 · Purchase (P): 2,200,000 (derivative) @ $16.00 | EDGAR |
| 2026-02-27 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 3,108 @ $3.79 · Sale (S): 3,108 @ $18.04 · Sale (S): 523 @ $18.04 · Option exercise (M): 3,108 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Cohlhepp Ryan — President and COO, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Raben David — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Hyep Ivan — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Meisner Lara — Chief Legal Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Cohlhepp Ryan — President and COO, Director | Sale (S): 3,828 @ $18.10 | EDGAR |
| 2026-01-26 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 1,882 @ $3.79 · Sale (S): 1,882 @ $18.15 · Option exercise (M): 1,882 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Cohlhepp Ryan — President and COO, Director | Sale (S): 149 @ $18.02 | EDGAR |
| 2025-12-29 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 25,000 @ $4.44 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Raben David — Chief Medical Officer | Option exercise (M): 19,789 @ $3.79 · Option exercise (M): 19,789 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Hyep Ivan — Chief Financial Officer | Option exercise (M): 9,200 @ $3.79 · Sale (S): 9,200 @ $18.31 · Option exercise (M): 9,200 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 29,500 @ $5.45 · Option exercise (M): 29,500 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Cohlhepp Ryan — President and COO, Director | Option exercise (M): 8,000 @ $3.79 · Sale (S): 8,000 @ $18.68 · Sale (S): 4,500 @ $18.68 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Raben David — Chief Medical Officer | Option exercise (M): 5,500 @ $3.79 · Sale (S): 5,500 @ $18.45 · Option exercise (M): 4,594 @ $3.79 · Sale (S): 4,594 @ $18.84 · Option exercise (M): 906 @ $3.79 · Sale (S): 906 @ $18.84 · +3 more | EDGAR |
| 2025-11-25 | 4 | Mazumdar Claire — Chief Executive Officer, Director | Option exercise (M): 41,163 @ $3.79 · Sale (S): 41,163 @ $18.86 · Option exercise (M): 41,163 (derivative) @ $0 | EDGAR |
Recent 8-K events — Bicara Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BCAX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →